Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.65 |
| ▸ | LARS1 | Q9P2J5 | 1/20 | 0.56 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.40 |
| ▸ | HRH2 | P25021 | 2/20 | 0.38 |
| ▸ | HRH1 | P35367 | 2/20 | 0.38 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14426761 | 1.00 | KCNH2 (0.65) | KCNH2LARS1DRD2HRH3HRH2 | |
| SCHEMBL14426770 | 0.97 | KCNH2 (0.64) | KCNH2LARS1DRD2HRH3CYP1A1 | |
| SCHEMBL5390274 | 0.97 | KCNH2 (0.64) | KCNH2LARS1DRD2HRH3CYP1A1 | |
| SCHEMBL14426758 | 0.96 | KCNH2 (0.63) | KCNH2LARS1DRD2HRH3CYP1A1 | |
| SCHEMBL14426774 | 0.96 | KCNH2 (0.63) | KCNH2LARS1DRD2HRH3CYP1A1 | |
| SCHEMBL5390236 | 0.96 | KCNH2 (0.63) | KCNH2LARS1DRD2HRH3CYP1A1 | |
| SCHEMBL5399118 | 0.96 | KCNH2 (0.63) | KCNH2LARS1DRD2HRH3CYP1A1 | |
| SCHEMBL14426773 | 0.96 | KCNH2 (0.63) | KCNH2LARS1DRD2HRH3CYP1A1 | |
| SCHEMBL5398726 | 0.96 | KCNH2 (0.63) | KCNH2LARS1DRD2HRH3CYP1A1 | |
| SCHEMBL14426755 | 0.96 | KCNH2 (0.63) | KCNH2LARS1DRD2HRH3CYP1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7259174-B2 | Imidazolidinone compounds | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2007-08-21 | — | — | US | disclosed |
| US-20050267164-A1 | Imidazolidinone compounds | NATIONAL HEALTH RESEARCH INSTITUTES | 2005-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267164-A1 | Imidazolidinone compounds | MLX, EPX, ZYX | KCNH2 1792/4885LARS1 4223/4885DRD2 4835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.